Blood Volume as a new functional image-based biomarker of progression in metastatic renal cell carcinoma

Aska Drļjevic-Nielsen1,2, Finn Rasmussen3, Jill Rachel Mains1, Kennet Thorup1 & Frede Donskov2*

RECIST v1.1 has limitations in evaluating progression. We assessed Dynamic Contrast Enhanced Computed Tomography (DCE-CT) identified Blood Volume (BV) for the evaluation of progressive disease (PD) in patients with metastatic renal cell carcinoma (mRCC). BV was quantified prospectively at baseline, after one month, then every three months until PD. Relative changes (ΔBV) were assessed at each timepoint compared with baseline values. The primary endpoint was Time to PD (TTP), the secondary endpoint was Time to the scan prior to PD (PDminus1). Cox proportional hazard models adjusted ΔBV for treatments and International mRCC Database Consortium factors. A total of 62 patients had analyzable scans at the PD timepoint. Median BV was 23.92 mL × 100 g⁻¹ (range 4.40–399.04) at PD and 26.39 mL × 100 g⁻¹ (range 8.70–77.44) at PDminus1. In the final multivariate analysis higher ΔBV was statistically significantly associated with shorter Time to PD, HR 1.11 (95% CI 1.07–1.15, P < 0.001). Also assessed at PDminus1, higher ΔBV was significantly associated with shorter time to PD, HR 1.14 (95% CI 1.01–1.28, P = 0.031). In conclusion, DCE-CT identified BV is a new image-based biomarker of therapy progression in patients with mRCC.

The rapid development of new therapies for metastatic renal cell carcinoma (mRCC), such as angiogenesis inhibitors and immune check-point inhibitors, has not been accompanied by a corresponding development in the response evaluation criteria. The current gold standard for evaluation of treatment response is the Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1), which provides only morphological information, while not taking into account physiological and biological changes within the tumor.

RECIST v1.1 defined progression (PD) is characterized by an increase > 20% in the sum of unidimensional diameters in up to 5 target lesions or the appearance of a new lesion. However, immune checkpoint inhibitors may lead to immune cell infiltration in the tumor tissue, resulting in inflammatory swelling, i.e., the tumor lesion increases in size or new lesions appear as part of pseudo-progression. Angiogenesis inhibitors can induce tumor necrosis leading to an increase in size of the tumor. Therefore, when monitoring treatment according to RECIST v1.1, an enlargement in the tumor can lead to interpretational distress over stopping therapy, as the patient may not necessarily have treatment failure. The clinical dilemma is real. Stopping therapy too early without unequivocal progression means abandoning efficient therapy; stopping therapy too late may be fatal, as approximately half of patients are lost to further treatment at the time of progression.

Dynamic contrast-enhanced computed tomography (DCE-CT) is a functional imaging modality consisting of repeated scans over a single target lesion (primary tumor or metastases) enabling an assessment of changes in contrast enhancement of the scanned tissue. Using advanced software techniques, these data can be used to calculate functional parameters, such as blood volume (BV) using histogram analysis. This parameter correlates to vascularity and provides additional information to the morphological information obtained from the routine Contrast-Enhanced CT (CE-CT).

DCT-CT identified BV at baseline was recently identified as a new, independent prognostic factor in patients with metastatic renal cell carcinoma (mRCC), that may add to the prognostic accuracy of International Metastatic renal cell carcinoma Database Consortium (IMDC) criteria. Early decline in DCE-CT parameters have shown to predicted treatment response and a favorable outcome in patients with mRCC treated with immunotherapy and targeted therapies. Even though it is well established that a high baseline BV was an independent
biomarker for favorable survival outcome, it remains to be assessed whether BV can be used as a biomarker for progression during treatment in patients with mRCC.

The aim of the study was to examine whether BV, identified by DCE-CT, could be used as an image-based biomarker of therapy progression in patients with mRCC.

**Materials and methods**

**Patients.** Patients with biopsy verified mRCC treated at Aarhus University Hospital, Denmark, were included from two prospective studies: the Angiogenesis Inhibitor Study (AIS) and the Danish Renal Cancer Group Study-1 (DaRenCa-1). Patients in the cohort study AIS (N = 33) were enrolled between January 2012 and September 2016 and were treated with first-line pazopanib (N = 12) (Votrient: Novartis Oncology, before 2015: GlaxoSmithKline), sunitinib (N = 12) (Sutent: Pfizer), or temsirolimus (N = 9) (Torisel: Pfizer Inc). The randomized phase II clinical trial DaRenCa-1 (N = 89) compared the effect of subcutaneously administered Interleukin 2 (IL-2) (aldesleukin, Proleukin: Novartis Vaccines and Diagnostics) and interferon alpha (IFN-α) (IFN-α2b, IntronA: Merck) with or without intravenously administered bevacizumab (N = 45 and N = 44, respectively) (Avastin: Genentech, Roche) in patients enrolled between October 2009 and November 2014. Treatment in both AIS and DaRenCa-1 cohorts was given until RECIST v1.1-defined progression.

The inclusion criteria for the DaRenCa Study-1 were: histologically verified clear cell mRCC, no prior oncologic treatment, measurable metastatic disease according to the RECIST v1.1 criteria, favorable or intermediate risk MSKCC group, Karnofsky Performance Status ≥ 70% and adequate kidney function (serum creatinine < 150 micromol/L). The inclusion criteria for AIS were: histologically verified mRCC, no prior oncologic treatment and adequate kidney function (estimated glomerular filtration rate (eGFR < 35 ml/min).

Using the same cohort of patients as in this current study, the association between baseline BV and survival outcome was assessed for baseline features and the association between DCT-CT parameters and early treatment response have been published.

Approval by the Central Denmark Region Ethics Committee and The Central Denmark Data Protection Agency was granted and written informed consent was obtained before inclusion started. The study was performed in accordance to the approved guidelines by the Central Denmark Region Ethics Committee and The Central Denmark Data Protection Agency. DaRenCa-1 was registered at ClinicalTrials.gov (identifier NCT01274273) and approved by the Danish Medicines Agency.

Electronic medical charts were used to retrieve information about baseline clinical factors, treatments and baseline IMDC prognostic factors.

A total of 105 patients (DaRenCa-1, N = 76 and AIS, N = 29) and 483 analyzable DCE-CT scans were included in the study, where 62 and 64 patients had an analysable DCE-CT scan at PD and the scan prior to PD (PDi minus1), respectively, Fig. 1.

**CE-CT and DCE-CT.** A routine contrast enhanced (CE) CT was performed at baseline and every 3 months until progression and was assessed according to RECIST v1.1. All clinical decisions were based on routine CE-CT scan results.

DCE-CT was performed at baseline, after 1 month of therapy and every three months until progression. Initially, a DCE-CT scan of a single target lesion was performed, followed by a routine CE-CT scan of the thorax, abdomen, and pelvis. Patients remained supine for 10 min between the scans. Based on prespecified protocol criteria, an experienced radiologist selected a representative target lesion that was optimal for functional imaging. The target lesions scanned with DCE-CT were located in the lung (N = 21), pleura (N = 5), supraclavicular/thoracic lymph nodes (N = 16), retroperitoneal lymph nodes (N = 8), kidney (N = 14), kidney bed (N = 6), adrenal gland (N = 3), bone (N = 12), liver (N = 8), pancreas (N = 7), extra/intra abdominal soft tissue (N = 3 and N = 2, respectively); the same DCE-CT technique was used irrespective of target lesion location.

Before each DCE-CT scan, 60 ml ioxilanox (Visipaque, GE Healthcare) 270 mg I/ml at 4 mL/s and 6 mL/s was administered intravenously. Before each routine CE-CT, ioxilanox (Visipaque, GE Healthcare) 270 mg I/ml based on body weight (maximum 180 ml) at 4 mL/s was administered intravenously. In the event of minor reactions to ioxilanox, patients were subsequently given iohexol (Omnipaque, GE Healthcare) 300 mg I/ml instead.

DCE-CT and CE-CT scans were performed using either Philips Brilliance 64 or iCT 256 (Philips Healthcare). DCE-CT consisted of 2-s scan cycles for a total of 70 s; median z-axis of 8 cm (range, 4–14.5 cm), median mAs of 100mAs (range, 100–210 mAs), and median kVp of 100 kVp (range, 80–180 kVp). The median dose length product was 1050.10 mGy x cm (range, 186.9–3009.00 mGy x cm) and the median computed tomography dose index was 131.29 mGy (range, 18.80–296.27 mGy).

Routine CE-CT scans were obtained using attenuation based current modulation; 120 kVp of peak voltage, 0.75 s of rotation time, a collimation of 64/128 × 0.625 mm, and a pitch of 0.925.

**4D imaging analysis.** The prototype software program Advanced Perfusion and Permeability Application, Philips (Philips, Healthcare) was used to analyze DCE-CT data in four dimensions (4D). After loading the dynamic data, a spatial filtration and motion correction was performed using a non-rigid registration. The software program used the deconvolution method to calculate BV (mL×100 g⁻¹) and display corresponding BV maps.

Data were then loaded into Intellispace 6.0 Multimodality Tumor Tracking (Philips, Healthcare). A semi-quantitative three dimensional (3D) sculpt-tool was used to delineate the target lesion as the Volume of Interest (VOI) using the morphological DCE-CT images at arterial peak enhancement. When the 3D analysis was combined with the time dimension in DCE-CT due to repeated measurements, it resulted in a 4D analysis. A
radiologist, blinded to the treatment group and survival outcomes, performed all the analyses. This particular method has previously shown excellent interobserver correlations17.

MATLAB (v. R2015b, MathWorks Inc.) was used to analyze the dynamic BV data based on the VOI on DCE-CT images at peak arterial enhancement. Histogram values of BV were extracted based on the DCE-CT VOI using in-house programmed scripts. The median values for BV was calculated for each histogram and used for assessment, as this value previously has shown the best correlation with patient outcome in mRCC17.

**Statistical analysis.** Compared to baseline, relative changes in BV were calculated in percent (%) at each scan timepoint ($X_{\text{timepoint}}$) until RECIST v1.1 defined PD:

![Flowchart of prospectively included patients with mRCC](image-url)
ΔBV was assessed as continuous variables presented as 20-percent point increasements at each timepoint. Univariate and multivariate Cox proportional hazards models were used to examine the association between ΔBV and PD using two different endpoints. The primary endpoint was TTP and the secondary endpoint was Time to the scan prior to PD (PDminus1), i.e. to assess if PD could be detected on the scan one timepoint earlier. For patients experiencing cancer related death or PD due to clinical evaluation or supplementary imaging, a consensus was made regarding classification of the latest DCE-CT scan being either PD (N = 9) or PDminus1 (N = 4) events.

The effect between treatment groups and ΔBV were examined by constraining the multivariate analyses to the patients treated with angiogenesis inhibitors and the immunotherapy, respectively. The proportional hazards assumptions were tested graphically by Schoenfeld residuals against the time and were fulfilled.

The median follow-up in alive patients was assessed using the reverse Kaplan–Meier survival curves. A Receiver Operating Characteristic (ROC) analysis was performed to identify a possible cut-off at PD and PDminus1 for the relative change in the continuous DCE-CT parameters that were deemed significant in the multivariate Cox regression analysis. The ROC generated area under the curve (AUC) < 0.8 was considered not to have predictive value and was therefore not eligible for estimating a cut-off value. All tests were two-sided and P values below 0.05 were considered as statistically significant. IBM SPSS Statistics for Windows (Version 27.0, IBM Corp.) was used to perform all statistical analyses.

Results

Patients. Baseline patient characteristics are presented in Table 1.

At the time of primary diagnosis approximately half of the included patients had T1–T2 disease (48%), while the other half had T3–T4 disease (51%). Negative nodal status (N0) was seen in 57 patients (54%), while 25 patients (24%) had a positive nodal status (N1) and 23 patients (22%) had an unknown nodal status (NX). A total of 6 patients (6%) had a history of previous cancer five years prior to the mRCC diagnosis (basal cell carcinoma (N = 1) and caecum adenocarcinoma (N = 1)).

All included patients were naïve to systemic oncological treatment and received 1st line oncological treatment. Most patients had a prior nephrectomy (83%), 16 patients (15%) had prior excision of a metastasis and 4 patients (4%) had prior radiotherapy. The majority were male (73%), had clear cell histology (93%), and 57% had synchronous cancer (presence of metastatic disease ≤ 3 months of initial cancer diagnosis); 15% had sarcomatoid differentiation. According to the IMDC criteria, 21% were favorable, 53% intermediate, and 26% poor prognostic category, Table 1.

The median Time to PD was 9.15 months (95% CI 6.87–11.42) and the median follow-up in alive patients was 66.07 months (95% CI 32.36–99.78). The baseline target lesion volume was at median 18.32 cm³ (range 0.90–572.10) and baseline median BV was 32.87 mL × 100 g⁻¹ (range 9.52–92.87).

Baseline anemia, HR 1.56 (95% CI 1.04–2.36, P = 0.033) and baseline neutrophilia, HR 2.89 (95% CI 1.65–5.08, P < 0.001) were associated with shorter time to progression, Table 2.

Univariate analyses of relative changes in BV. Median BV at PD was 23.92 mL × 100 g⁻¹ (range 4.40–399.04) and was 26.39 mL × 100 g⁻¹ (range 8.70–77.44) at PDminus1. In univariate analysis, a higher ΔBV was associated with shorter time to PD, HR 1.11 (95% CI 1.07–1.15, P < 0.001).

Multivariate analysis of relative changes in BV. In the final multivariate analysis, higher ΔBV were independently associated with a shorter time to PD, HR 1.11 (95% CI: 1.07–1.15, P < 0.001), Fig. 2 and Table 3.

Also assessed at PDminus1 an higher ΔBV were independently associated with shorter time to PD, HR 1.14 (95% CI 1.01–1.28, P = 0.031), Fig. 3 and Table 4.

Performing the analyses constricted to patients with clear cell RCC, higher ΔBV remained independently associated with a shorter time to PD, HR 1.13 (95% CI: 1.09–1.17, P < 0.001) and PDminus1, HR 1.24 (95% CI: 1.10–1.40, P < 0.001).

Constricting the multivariate analyses to patients treated with angiogenesis inhibitors, higher ΔBV remained independently associated with a shorter time to PD, HR 1.09 (95% CI: 1.03–1.16, P = 0.002), but no association was found at PDminus1. For patients treated with immunotherapy, higher ΔBV remained independently associated with a shorter time to PD, HR 1.15 (95% CI: 1.06–1.25, P < 0.001) and PDminus1, HR 1.26 (95% CI: 1.05–1.53, P = 0.011), respectively.

Receiver operating characteristic analysis. AUC for ΔBV was 0.494 (95% CI 0.249–0.694) at PD and 0.468 (95% CI 0.256–0.679) at PDminus1.
Table 1. Baseline characteristics. ULN Upper Limit of Normal, LLN Lower Limit of Normal, IL-2 Interleukin-2, IFN-α interferon alpha, IMDC International Metastatic Renal Cell Carcinoma Consortium.

| Factor                                      | N (%)         |
|---------------------------------------------|---------------|
| Total                                       | 105 (100)     |
| Gender                                      |               |
| Male                                        | 77 (73.3)     |
| Female                                      | 28 (26.7)     |
| IMDC group                                  |               |
| Favorable                                   | 22 (21.0)     |
| Intermediate                                | 56 (53.3)     |
| Poor                                        | 27 (25.7)     |
| Karnofsky Performance status < 80%          | 5 (4.8)       |
| Interval between RCC diagnosis and 1st line therapy < 1 year | 77 (73.3) |
| Hemoglobin < LLN                            | 57 (54.3)     |
| Neutrophils > ULN                           | 16 (15.2)     |
| Trombocytes > ULN                           | 24 (22.9)     |
| Albumin corrected calcium > ULN             | 11 (10.5)     |
| Histology                                   |               |
| Clear cell                                  | 98 (93.3)     |
| Non clear cell                              | 7 (6.7)       |
| Prior nephrectomy                           |               |
| Yes                                         | 87 (82.9)     |
| No                                          | 18 (17.1)     |
| Synchronous metastatic disease              |               |
| Yes                                         | 60 (57.1)     |
| No                                          | 45 (42.9)     |
| Sarcomatoid differentiation                 |               |
| Yes                                         | 16 (15.2)     |
| No                                          | 89 (84.8)     |
| Treatment                                   |               |
| IL-2 and IFN-α                              | 37 (35.3)     |
| IL-2, IFN-α and bevacizumab                 | 39 (37.1)     |
| Sunitinib, pazopanib or temsirolimus        | 29 (27.6)     |

Table 2. Univariate association of baseline characteristics with time to progression. TTP Time to progression, ULN Upper Limit of Normal, LLN Lower Limit of Normal, IL-2 Interleukin-2, IFN-α interferon alpha.

| Factor                                      | TTP             | P     |
|---------------------------------------------|-----------------|-------|
| Individual IMDC risk factors:               |                 |       |
| Karnofsky Performance status < 80%          | 2.49 (1.00;6.21)| 0.051 |
| Interval between RCC diagnosis and 1st line therapy < 1 year | 1.61 (1.00;2.59) | 0.052 |
| Hemoglobin < LLN                            | 1.56 (1.04;2.36)| 0.033 |
| Neutrophils > ULN                           | 2.89 (1.65;5.08)|< 0.001 |
| Trombocytes > ULN                           | 1.51 (0.95;2.41)| 0.081 |
| Albumin corrected calcium > ULN             | 1.22 (0.63;2.35)| 0.556 |
| Prior nephrectomy                           | 0.82 (0.48;1.42)| 0.480 |
| Female gender                               | 1.43 (0.91;2.27)| 0.122 |
| Age above median (> 60.1 years)             | 0.72 (0.48;1.09)| 0.118 |
| Treatment group                             |                 |       |
| IFN-α and IL-2                              | Reference       |       |
| IFN-α, IL-2 and bevacizumab                 | 0.65 (0.39;1.11)|       |
| Sunitinib, pazopanib or temsirolimus        | 0.81 (0.51;1.30)|       |
Discussion
This study is the first to demonstrate that higher DCE-CT identified ΔBV is a new image-based biomarker of therapy progression in patients with mRCC. Our results show that patients with a 20%-point higher ΔBV have...
a 11% higher risk of having RECIST defined PD on the current conventional CT scan, indicating that the relative change in BV can be used as a biomarker to predict progression at the timepoint of RECIST v.1.1 defined progression. Furthermore, we find that patients with a 20%-point higher ΔBV without RECIST v.1.1 defined PD on the current conventional CT scan have a 14% higher risk of RECIST v.1.1 defined PD on the subsequent scan, suggesting that this biomarker may predict progression at the scan prior to RECISTv.1.1 defined progression. These findings strengthen the utility of BV as a biomarker for progression. Therefore, DCE-CT identified BV may have the potential to be used as a helper to RECIST v.1.1 in identifying PD in patients with mRCC and may have the potential to support clinical decision-making during treatment monitoring in mRCC, when RECIST v.1.1 is uncertain. However, it was not possible to define a cut off value for BV, limiting the implementation in the clinical setting. Further development in DCE-CT functional imaging in a larger cohort is encouraged, and is needed before it can reach clinical daily life in treatment decision making.

The association between ΔBV and PD was independent of treatment group at the timepoint of RECIST v.1.1 defined progression. However, at the timepoint prior to RECISTv.1.1 defined progression, the association was only significant for patients treated with IL-2 based therapies. These findings could indicate that BV increases more rapidly in patients treated with angiogenesis inhibitor. Further research assessing this matter in a larger cohort is encouraged.

RECIST v.1.1 relies solely on morphological information and because changes in tumor size may lag behind pathophysiological changes within the tumor, it is a suboptimal response evaluation tool for patients treated with targeted therapy. Characterizing unequivocal progression and changing therapy to the next treatment line at the appropriate time using RECIST v.1.1 can be difficult. In the randomized phase III trial comparing pazopanib and sunitinib as first-line therapy in mRCC patients, only half of the patients continued to second-line treatment after PD. Pseudoprogression has not been described in the literature on IL-2 immunotherapy and was not observed in this current study. However, pseudoprogression is a challenge during checkpoint immunotherapy and was highlighted in the study of Escudier et al., where the survival rate almost doubled in patients treated with nivolumab beyond RECIST v.1.1 defined progression. These studies illustrate and highlight the clinical dilemma of stopping therapy too late or too early.

The increasing need for a better response evaluation tool has led to attempts to improve the RECIST v.1.1 criteria. Choi was the first to combine morphological and functional information measured as CT contrast uptake in a target lesion on CE-CT. However, the CT contrast uptake was only measured in a single slice making it a major limitation due to intratumoral heterogenicity. The method in this current study evaluated the entire target lesion and thus took into account the intratumoral heterogenicity, making this method superior to the single slice method.

DCE-CT derived BV is a robust parameter, independent of changes in cardiac output, as described by Miles et al. BV values can be affected by motion and beam hardening artifacts, which can be minimized by instruction in shallow breathing, and by avoiding target lesions close to prosthetics or areas with high concentrations of contrast media agents.

Several studies, focusing on the prognostic significance of DCE-CT parameters at baseline, as well as the evaluation of early treatment response in mRCC, have been conducted. The study of Drljevic-Nielsen et al. showed that high baseline BV was a favorable independent prognostic factor for survival outcome, while the studies of Mains et al. showed that early reduction in BV was associated with favorable outcomes, whereas only a smaller reduction or an increase in BV were associated with worse outcomes. Our study is the first to demonstrate that a relative higher BV, when compared with baseline, was associated with a higher risk of PD and thus a worse outcome. Summarized, a higher BV at baseline is a favorable feature, whereas an higher ΔBV to demonstrate that a relative higher BV, when compared with baseline, was associated with a higher risk of PD and thus a worse outcome. Summary, a higher BV at baseline is a favorable feature, whereas an higher ΔBV is needed before it can reach clinical daily life in treatment decision making.

| Factor                       | Time to PD          |
|------------------------------|---------------------|
| **HR (95% CI)**              | **P**               |
| A Blood volume               | 1.11 (1.07;1.15)    | <0.001 |
| Interval between RCC diagnosis and 1st line therapy < 1 year | 1.81 (1.10;2.96) | 0.018 |
| Neutrophils > ULN            | 2.46 (1.10;5.48)    | 0.026 |
| Treatment group              |                     | 0.040 |
| IFN-α and IL-2               | Reference           |       |
| IFN-α, IL-2 and bevacizumab  | 0.96 (0.58;1.56)    |       |
| Sunitinib, pazopanib or temsirolimus | 0.44 (0.23;0.86) |       |

Table 3. Multivariat association at PD. The table exhibits factors that remained significant in the final multivariate analysis. PD progressive disease, IL-2 Interleukin-2, IFN-α interferon alpha.
the relative short Z-axis of DCE-CT (8 cm). A single target lesion was chosen, but this lesion was not necessarily representative of other target lesions in the same patient due to intertumoral heterogenicity. A fifth limitation is that the clinical decision making based on RECIST1.1 in this study represents a bias, as RECIST v1.1 may not

Figure 3. A patient with mRCC and a bronchopulmonary metastasis (purple arrow) on a routine CE-CT (A) at baseline and (B) the scan prior to progression, PDminus1; and DCE-CT (C) at baseline and (D) at PD. (E) The BV histograms of the metastasis depicts an increase in median BV values from baseline (21.57 mL×100 g\(^{-1}\)) to PDminus1 (28.85 mL×100 g\(^{-1}\)). CE-CT contrast enhanced Computed-Tomography, DCE-CT dynamic Contrast enhanced Computed-Tomography, PDminus1 scan prior to progressive disease.
nesearily identify PD at the true time point. Finally, a cut-off value could not be defined in this study, limiting the clinical utility of these parameters in daily clinical practice.

**Conclusions**

In conclusion, DCE-CT identified BV is a new image-based biomarker of therapy progression in patients with mRCC.

**Data availability**

The datasets generated and/or analyzed during the current study are not publicly available due to further analysis of data for upcoming publications, but are available from the corresponding author on reasonable request.

Received: 11 January 2021; Accepted: 21 September 2021
Published online: 04 October 2021

**References**

1. Gerwing, M. et al. The beginning of the end for conventional RECIST-novel therapies require novel imaging approaches. *Nat. Rev. Clin. Oncol.* 16(7), 442–458 (2019).

2. Eisenhauer, E. A. et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). *Eur. J. Cancer* 45(2), 228–47 (2009).

3. Schwartz, L. H. *Kidney Cancer* (3), 553–562 (2013).

4. Litiere, S., Collette, S., de Vries, E. G., Seymour, L. & Bogaerts, J. RECIST - learning from the past to build the future. *Nat. Rev. Clin. Oncol.* 14(3), 187–192 (2017).

5. Seymour, L. et al. iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics. *Lancet Oncol.* 18(3), e143–e154 (2017).

6. Fournier, L. et al. Imaging response of antiangiogenic and immune-oncology drugs in metastatic renal cell carcinoma (mRCC): current status and future challenges. *Kidney Cancer* 1(2), 107–114 (2017).

7. Soerensen, A. V. et al. Improved overall survival after implementation of targeted therapy for patients with metastatic renal cell carcinoma: results from the Danish Renal Cancer Group (DARENCA) study-2. *J. Clin. Oncol.* 30(3), 553–562 (2014).

8. Mozer, R. J., Hutson, T. E., McCann, L., Deen, K. & Choueiri, T. K. Overall survival in renal-cell carcinoma with pazopanib versus sunitinib. *N. Engl. J. Med.* 369(8), 722–731 (2013).

9. Mozer, R. J., Hutson, T. E., McCann, L., Deen, K. & Choueiri, T. K. Overall survival in renal-cell carcinoma with pazopanib versus sunitinib. *N. Engl. J. Med.* 370(18), 1769 (2014).

10. Miles, K. A. & Griffiths, M. R. Perfusion CT: a worthwhile enhancement?: *Br. J. Radiol.* 76(904), 220–231 (2003).

11. Miles, K. A. Perfusion imaging with computed tomography: brain and beyond. *Transl. Oncol.* 22(7), 1340–1441 (2012).

12. Dhrljevic-Nielsen, A., Rasmussen, F., Mains, J. R., Thorup, K. & Donskov, F. Baseline blood volume identified by dynamic contrast-enhanced computed tomography as a new independent prognostic factor in metastatic renal cell carcinoma. *Transl. Oncol.* 13(10), 108829. https://doi.org/10.1016/j.tranon.2020.108829 (2020).

13. Banting, G. et al. Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study. *Clin. Oncol.* 27(34), 5794–5799 (2009).

14. Main, J. R., Donskov, F., Pedersen, E. M., Madsen, H. H. T. & Rasmussen, F. Dynamic contrast-enhanced computed tomography as a potential biomarker in patients with metastatic renal cell carcinoma: preliminary results from the Danish Renal Cancer Group Study-1. *Invest. Radiol.* 49(9), 601–607 (2014).

15. Mains, J. R., Donskov, F., Pedersen, E. M., Madsen, H. H. T. & Rasmussen, F. Dynamic contrast-enhanced computed tomography-derived blood volume and blood flow correlate with patient outcome in metastatic renal cell carcinoma. *Invest. Radiol.* 52(2), 103–110 (2017).

16. Mains, J. R. et al. Use of patient outcome endpoints to identify the best functional CT imaging parameters in metastatic renal cell carcinoma patients. *Br. J. Radiol.* 91(1082), 20160795 (2018).

17. Mains, J. R. et al. Use of functional CT imaging parameters in metastatic renal cell carcinoma patients. *Br. J. Radiol.* 91(1082), 20160795 (2018).

18. Donskov, F., Jensen, N. V., Schmidt-Hansen, T., Broendum, L. & Geertsen, G. A randomized phase II trial of interferon-2 and interferon-alpha plus bevacizumab versus interferon-2 and interferon-alpha in metastatic renal-cell carcinoma (mRCC): results from the Danish Renal Cancer Group (DaRenCa) study-1. *Acta Oncol.* 57(5), 589–594 (2018).

19. Miles, K. A. & Griffiths, M. R. Perfusion CT: a worthwhile enhancement? *Br. J. Radiol.* 76(904), 220–231 (2003).

20. English, P. et al. A case for the use of receiver operating characteristic analysis of potential clinical efficacy biomarkers in advanced renal cell carcinoma. *Fut. Oncol.* 12(2), 175–182 (2016).

21. Ralain, M. J. & Eckhardt, S. G. Phase II studies of modern drugs directed against new targets: if you are fazed, too, then resist RECIST. *J. Clin. Oncol.* 22(22), 4442–4445 (2004).

22. Rosen, M. A. & Schnall, M. D. Dynamic contrast-enhanced magnetic resonance imaging for assessing tumor vascularity and vascular effects of targeted therapies in renal cell carcinoma. *Clin. Cancer Res.* 13(2), 777a–777b (2007).

23. Kang, H. et al. MRI assessment of early tumor response in metastatic renal cell carcinoma patients treated with sorafenib. *AJR Am. J. Roentgenol.* 200(1), 120–126 (2013).

**Table 4.** Multivariate association at PDminus1. The table exhibits factors that remained significant in the final multivariate analysis. **PDminus1** Scan prior to progressive Disease, IL-2 Interleukin-2, IFN-α interferon alpha.

| Factor | Time to PDminus1 | HR (95% CI) | P |
|--------|-----------------|-------------|---|
| A Blood volume | 1.14 (1.01;1.28) | 0.031 |
| Interval between RCC diagnosis and 1st line therapy <1 year | 1.95 (1.19;3.20) | 0.007 |
| Treatment group | | | 0.039 |
| IFN-α and IL-2 | Reference |
| IFN-α, IL-2 and bevacizumab | 1.16 (0.75;1.79) | |
| Sunitinib, pazopanib and temsirolimus | 0.52 (0.28;0.97) | |
24. Smith, A. D., Shah, S. N., Rini, B. I., Lieber, M. L. & Remer, E. M. Morphology, Attenuation, Size, and Structure (MASS) criteria: assessing response and predicting clinical outcome in metastatic renal cell carcinoma on antiangiogenic targeted therapy. *AJR Am. J. Roentgenol. 194*(6), 1470–1478 (2010).

25. Escudier, B. *et al.* Treatment beyond progression in patients with advanced renal cell carcinoma treated with nivolumab in checkmate 025. *Eur. Urol.* 72(3), 368–376 (2017).

26. van der Veldt, A. A., Meijerink, M. R., van den Eertwegh, A. J., Haanen, J. B. & Boven, E. Choi response criteria for early prediction of clinical outcome in patients with metastatic renal cell cancer treated with sunitinib. *Br. J. Cancer* 102(5), 803–809 (2010).

27. Fournier, L. S. *et al.* Metastatic renal carcinoma: evaluation of antiangiogenic therapy with dynamic contrast-enhanced CT. *Radiology* 256(2), 511–518 (2010).

28. Ng, C. S. *et al.* Perfusion CT in patients with metastatic renal cell carcinoma treated with interferon. *AJR Am. J. Roentgenol.* 194(1), 166–171 (2010).

29. Beksaç, A. T., Paulucci, D. J., Blum, K. A., Yadav, S. S. & Sfakianos, J. P. Badani KK (2017) Heterogeneity in renal cell carcinoma. *Urol. Oncol.* 35(8), 507–515 (2017).

Acknowledgements

We wish to acknowledge Philips Healthcare, who provided the software used for the imaging analysis and Roche and Novartis, who supported the clinical part of the study financially, but were not involved in the imaging analysis. We also wish to acknowledge Ipsen and The Health Research Foundation of Central Denmark for supporting the study financially. Furthermore, we wish to acknowledge Leslie Foldager from Aarhus University for providing statistical guidance.

Author contributions

A.D.N.: Conceptualization, Formal analysis, Investigation, Writing-Original Draft. F.R.: Conceptualization, Investigation, Formal analysis, Writing-Review & Editing, Funding acquisition, Supervision. J.R.M.: Conceptualization, Formal analysis, Investigation, Writing-Review & Editing, Supervision. K.T.: Formal analysis, Software, Writing-Review & Editing. F.D.: Conceptualization, Formal analysis, Investigation, Writing—Review & Editing, Funding acquisition, Supervision. All authors have approved the manuscript for submission.

Competing interests

A. Drljevic-Nielsen reports receiving research grants from Ipsen, The Maersk Foundation and The Health Research Foundation of Central Denmark Region and conference travels from Pfizer and Ipsen. F. Donskov reports receiving research grants from Pfizer, MSD and The Health Research Foundation of Central Denmark Region. J.R. Mains reports receiving research grants from the Memorial Foundation of Eva and Henry Fraenkel, The Health Research Foundation of Central Denmark Region and conference travels from Pfizer. No potential conflicts of interest were disclosed by F. Rasmussen and K. Thorup.

Additional information

Correspondence and requests for materials should be addressed to F.D.

Reprints and permissions information is available at www.nature.com/reprints.

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2021